Sweetening the pot

Why KaNDy plans to develop a women’s health therapy as a single-asset company

KaNDy Therapeutics Ltd. believes its first venture round as an independent company will fund development of a non-hormonal therapy for menopausal symptoms that will be ready for a Phase III trial by 2020.

Longitude Capital led KaNDy’s £25 million ($31.9 million) series C round, announced Aug. 29. The company’s series A and B rounds took

Read the full 544 word article

User Sign In